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OBJECTIVES: To summarize selected meta-analyses and trials related to critical 
care pharmacotherapy published in 2020.
DATA SOURCES: The Clinical Pharmacy and Pharmacology Pharmacotherapy 
Literature Update group screened 36 journals monthly for impactful publications.
STUDY SELECTION: The group reviewed a total of 119 articles during 2020 
according to relevance for practice.
DATA EXTRACTION: Articles were selected with consensus and importance 
to clinical practice from those included in the monthly Clinical Pharmacy and 
Pharmacology Pharmacotherapy Literature Update. The group reviewed articles 
according to Grading of Recommendations, Assessment, Development, and 
Evaluations criteria. Articles with a 1A grade were selected.
DATA SYNTHESIS: Several trials were summarized, including two meta-anal-
yses and five original research trials. Original research trials evaluating vitamin 
C, hydrocortisone, and thiamine versus hydrocortisone in sepsis, the use of non-
sedation strategies, dexmedetomidine in cardiac surgery, remdesivir for severe 
acute respiratory syndrome coronavirus 2, and thrombectomy in acute ischemic 
stroke. Two meta-analyses determining the impact of norepinephrine initiation in 
patients with septic shock and the use of corticosteroids in severe acute respira-
tory syndrome coronavirus 2 was included.
CONCLUSIONS: This clinical review provides summary and perspectives of clinical 
practice impact on influential critical care pharmacotherapy publications in 2020.
KEY WORDS: coronavirus disease 2019; critical care; drug therapy; review; 
sedation; septic shock
Critical care practitioners commit significant time staying up-to-date with the most pertinent medical literature (1). As such, clinicians rely on electronic table of contents, social media, blogs, and article synop-
ses to provide a summary of relevant literature (2). In 2009, a group of critical 
care pharmacists developed a process for updating practitioners on new crit-
ical care pharmacotherapy literature resulting in the Clinical Pharmacy and 
Pharmacology Pharmacotherapy Literature Update (CPPPLU), a monthly pub-
lication summarizing new literature. Currently, under the Clinical Pharmacy 
and Pharmacology (CPP) Section of the Society of Critical Care Medicine 
(SCCM), monthly reviews continue with annual review of the most impactful 
literature for the year (3–6).
MATERIALS AND METHODS
Monthly, the CPPPLU workgroup evaluates and selects articles relevant to 
critical care practice systematically from 36 journals based on importance 
and relevance to practice (Appendix A). For inclusion, articles must meet the 
following criteria: 1) controlled trial, observational, meta-analysis or major 
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guideline/guideline update; 2) adult patient popu-
lation; 3) addresses critical care and involving drug 
therapy (including fluid and nutritional therapy, drug-
impregnated lines, and dialysis in the ICU or percu-
taneous coronary interventions); and 4) published in 
current monthly issue. Articles that do not meet such 
criteria and those that are published online ahead-of-
print are excluded. CPPPLU members are assigned 
journals for monthly evaluation and abstraction and 
assign a Grading of Recommendations, Assessment, 
Development, and Evaluations (GRADE) score upon 
extraction (7). Currently, the CPPPLU is distributed 
globally to the membership of SCCM through a web-
based platform and social media. From 119 articles 
reviewed in 2020, articles that were GRADE 1A were 
evaluated for annual review. Articles that appeared to 
have high impact were selected in addition to consid-
eration for breadth of critical care medication cate-
gory and specialty pertinence. All authors agreed with 
selected content and the article as well as its content 
were approved by the SCCM CPP Steering Committee 
and SCCM Council.
RESULTS
Over the course of the year, 26 articles were analyzed 
for inclusion into this article. Two meta-analyses and 
five clinical research trials were selected for review for 
this annual publication on the basis of GRADE criteria 
(1A), pharmacotherapeutic focus, and expected prac-
tice influence (8–13). Table 1 provides a summary of 
the studies selected for discussion.
DISCUSSION
Coronavirus Disease 2019
Remdesivir in Adults With Severe Coronavirus 
Disease 2019: A Randomized, Double-Blind, Placebo-
Controlled, Multicenter Trial. This randomized, pla-
cebo-controlled, double-blind trial evaluated remdesivir 
200 mg on day one followed by 100 mg daily on days 2–10 
in hospitalized adults with severe, laboratory-confirmed 
coronavirus disease 2019 (COVID-19) pneumonia (11). 
Those exhibiting oxygen saturation of less than or equal 
to 94% on room air or an Pao2 to Fio2 ratio of less than 
or equal to 300 mm Hg within 12 days of symptom 
onset were included. Median time from symptom onset 
to treatment randomization was 10 days. The majority 
of patients were categorized at baseline as a “three” on 
6-point clinical status ordinal scale (six = death, three = 
hospitalized with supplemental oxygen, one = discharge 
eligible). The trial was terminated early due to control of 
the outbreak in Wuhan, reducing statistical power from 
80% to 58% (n–237).
In the intention to treat analysis, remdesivir showed 
no difference in time to clinical improvement (21 d vs 23 
d; hazard ratio, 1.23; 95% CI, 0.87–1.75) or 28-day mor-
tality (14% vs 13%; difference, 1.1%; CI, –8.1 to 10.3). 
Those receiving remdesivir within 10 days of symptom 
onset exhibited a numerically faster time to clinical 
improvement and numerically higher clinical im-
provement rates at days 14 and 28. Ultimately, rem-
desivir conferred no statistical difference in either 
clinical improvement or mortality compared with pla-
cebo, although severely underpowered due to early 
termination.
Numerous trials have evaluated remdesi-
vir for COVID-19 displaying similar results. The 
Adaptive COVID-19 Treatment Trial-1 study dem-
onstrated significantly reduced time to recovery 
(10 vs 15 d; recovery rate ratio [RR], 1.29; 95% CI, 
1.12–1.49; p < 0.001) and higher clinical improve-
ment scores at day 15 (odds ratio [OR], 1.5; 95% 
CI, 1.2–1.9; p < 0.001) with remdesivir (15). Specifically, 
the subgroup of patients requiring supplemental ox-
ygen (not via means of high-flow nasal cannula or 
noninvasive ventilation) and those receiving treatment 
less than 10 days from symptom onset gleaning the 
most benefit. The World Health Organization (WHO) 
Solidarity trial compliments this, finding no mortality 
benefit (RR, 0.95; 95% CI, 0.81–1.11; p = 0.50), but nu-
merically lower deaths in lower risk patients not requir-
ing ventilation (RR, 0.80; 95% CI, 0.63–1.01) (16). 
Aforementioned trials included 10-day remdesivir 
courses; however, studies evaluating 5- and 10-day 
courses revealed no difference in clinical status or im-
provement between the two durations (17, 18).
Wang et al (11), combined with available literature, 
may suggest a role for 5 days of remdesivir in low-risk, 
hospitalized patients receiving noninvasive oxygenation 
within 10 days of symptom onset to prevent risk of de-
terioration. Remdesivir may curtail duration of illness, 
expediting time to hospital discharge, which could greatly 
impact limited healthcare resources. Current guidelines 
recommend against its use in patients on invasive ven-
tilation or extracorporeal membrane oxygenation (19).
Systematic Review
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TABLE 1. 
Article Summary
References Population Intervention Design Outcomes
Fujii et al (8) Two-hundred eleven patients 
with septic shock, 
vasopressor dependent 










No difference in time alive and free of 
vasopressors at day 7
Li et al (13) Nine-hundred twenty-nine 
adult patients with septic 
shock
Early vs later 
norepinephrine 
initiation














No difference in all-cause 90-d 





adult patients undergoing 
cardiac surgery with 
cardiopulmonary bypass and 





No difference in postoperative atrial 
fibrillation








Group et al 
(14)
One-thousand seven-







Decreased 28-d mortality with 
steroids
Minimal heterogeneity reported, but 

















adults with large vessel 
occlusion and National 
Institute of Health Stroke 
Scale of at least two
Thrombectomy 






Modified Rankin score at 90 d 
with thrombectomy alone vs 
combination was noninferior
No difference in mortality, severe 
adverse events, or procedural 
complications
COVID-19 = coronavirus disease 2019.
WHO Rapid Evidence Appraisal for COVID-19 
Therapies (REACT) Working Group et al. Administration 
of Systemic Corticosteroids and Mortality Among Critically 
Ill Patients With COVID-19: A Meta-Analysis. The use of 
corticosteroids for the treatment of viral pneumonias has 
been a widely debated controversy (14). Prior to the publica-
tion of studies evaluating its effect in severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), practice guidelines 
from multiple organizations cautioned against the rou-
tine use of corticosteroids in patients with COVID-19 
pneumonia (20). This recommendation was largely 
based on experiences with other viruses such as in-
fluenza, SARS-CoV, and Middle East respiratory syn-
drome coronavirus, in which corticosteroids have 
been associated with delayed viral clearance and worse 
clinical outcomes (21, 22). However, corticosteroids 
became standard practice for the treatment of COVID-
19 pneumonia after the publication of the Randomized 
Evaluation of COVID-19 Therapy (RECOVERY) trial 
that suggested a mortality benefit (23).
Bissell et al
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The WHO Rapid Evidence Appraisal for COVID-19 
Therapies (REACT) Working Group conducted a pro-
spective meta-analysis of randomized trials to estimate 
the association between corticosteroids versus usual 
care or placebo and 28-day all-cause mortality in hos-
pitalized, critically ill patients with COVID-19 (14). 
Trials were identified by trial registries until April 2020 
and data were pooled from patients recruited to trials 
by June 9, 2020. Patients recruited after the release of 
the results of the RECOVERY trial were not included 
in the analysis. Of 16 trials identified, seven were in-
cluded in the final meta-analysis with 1,703 critically ill 
patients (678 to corticosteroids and 1,025 to usual care/
placebo). Corticosteroid therapies included low and 
high-dose dexamethasone (three studies), low-dose 
hydrocortisone (three studies), and high-dose methyl-
prednisolone (one study). A majority of patients were 
on mechanical ventilation (91.5%), and 47% were on 
vasoactive agents at randomization. Five trials reported 
mortality at 28 days, one at 21 days, and one at 30 days.
The primary outcome, all-cause mortality at 28 
days, was lower in the steroid arm compared with 
the no steroid arm based on a fixed-effect meta-anal-
ysis (32.7% vs 41.5%; OR, 0.66; 95% CI, 0.53–0.82; 
p < 0.001). Dexamethasone was associated with lower 
all-cause mortality (OR, 0.64; 95% CI, 0.50–0.82; 
p < 0.001), while hydrocortisone (OR, 0.69; 95% CI, 0.43–
1.12; p = 0.13) and methylprednisolone (OR, 0.91; 95% 
CI, 0.29–2.87; p = 0.87) were not. In subgroup analy-
ses, among patients receiving invasive mechanical 
ventilation, the OR for mortality associated with corti-
costeroids compared with usual care was 0.69 (95% CI, 
0.55–0.86) and among those that were not on invasive 
ventilation, the OR was 0.41 (95% CI, 0.19–0.88). There 
was also a stronger association between corticosteroids 
and lower mortality in patients who were not receiving 
vasoactive medications (OR, 0.55; 95% CI, 0.34–0.88) 
than those who were (OR, 1.05; 95% CI, 0.65–1.69).
The authors concluded that corticosteroid adminis-
tration was associated with a lower all-cause mortality 
without evidence suggesting an increased risk of se-
rious adverse events (14). The analysis reports minimal 
heterogeneity with I2 of 15.6% (p = 0.31); however, the 
included trials had substantial differences in the defi-
nition of illness, steroid choice and dose, duration of 
therapy, and reporting of adverse events. Particularly, 
the three steroids used have different durations of ac-
tivity, dosing strategies, and potency of mineralocor-
ticoid or glucocorticoid activities. The RECOVERY 
trial, which used low-dose dexamethasone, contrib-
uted 57% of the weight in the primary outcome of all-
cause mortality. In contrast, only one study evaluated 
the effect of methylprednisolone and contributed 3.5% 
of the weight in the primary analysis. Given the high 
percentage of patients receiving dexamethasone in this 
analysis, the mortality benefit of alternative steroids, 
such as methylprednisolone remains to be determined. 
Uncertainties remain in regards to appropriate dosing 
and duration of corticosteroids in different severities 
of critical illness or ventilatory support, as well as the 
additive effect of adjunctive therapies for COVID-19 
such as remdesivir.
Sepsis and Septic Shock
Effect of Vitamin C, Hydrocortisone, and Thiamine 
Versus Hydrocortisone Alone on Time Alive and Free 
of Vasopressor Support Among Patients With Septic 
Shock (VITAMINS). The VITAMINS trial was a multi-
center, open-label, parallel-group, randomized controlled 
trial (RCT) evaluating resolution of shock with vitamin 
C (1.5 g every 6 hr), hydrocortisone (50 mg every 6 hr), 
and thiamine (200 mg every 12 hr) (HAT) therapy (8). 
Patients in septic shock who were vasopressor de-
pendent for at least 2 hours were randomized to HAT 
therapy (n = 107) versus the control group of hydrocor-
tisone alone (n = 104) with treatment durations until 
shock resolution or up to 10 days.
Baseline characteristics were similar between 
groups, except the HAT therapy group had numerically 
higher lactate levels (median, 4.2 vs 3.3 mmol/L). Mean 
baseline Sequential Organ Failure Assessment (SOFA) 
scores were similar in the HAT and control groups (8.6 
vs 8.4, respectively). There was no difference in the pri-
mary outcome of time alive and free of vasopressors 
at day 7 (median 122.1 vs 124.6 hr in HAT therapy vs 
control group, respectively; p = 0.83) or 28- and 90-day 
mortality. The change in SOFA score was significantly 
greater with HAT therapy at day 3 compared with the 
control group (median –2 vs –1; p = 0.02). The mean 
duration of either therapy was 3.4 days.
In 2017, Marik et al (24) observed a significant re-
duction in duration of vasopressor use and hospital 
mortality in patients with severe sepsis or septic shock 
who received HAT therapy versus standard of care. 
This set forth several trials evaluating the impact of 
HAT combination on morbidity and mortality out-
comes, each with slightly different study designs. The 
Systematic Review
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VITAMINS study, which only enrolled septic shock 
patients with the control arm receiving hydrocorti-
sone, disputed the Marik et al (24) findings, as there 
was no difference in the primary outcome or sec-
ondary outcomes of 28- and 90-day mortality (8). 
The improvement in SOFA score at day 3 in the HAT 
therapy group was not corroborated in two additional 
studies at 4 days and 72 hours, respectively (8, 25, 26). 
Both the Outcomes of Metabolic Resuscitation Using 
Ascorbic Acid, Thiamine, Glucocorticoids in the Early 
Treatment of Sepsis (ORANGES) and Ascorbic Acid, 
Corticosteroids, and Thiamine in Sepsis (ACTS) trials 
found faster time to resolution of shock in the HAT 
therapy group versus placebo, unlike the VITAMINS 
trial (25, 26). However, there is well-established evi-
dence that the use of hydrocortisone reduces time to 
resolution of shock and only 41% and 14% of patients 
in the placebo arms of the ORANGES and ACTS trials 
received corticosteroids, respectively (27, 28). Current 
available evidence does not support the routine use of 
HAT therapy over hydrocortisone alone for resolution 
of shock or for improvement of mortality in patients 
with sepsis.
Timing of Norepinephrine Initiation in Patients With 
Septic Shock: A Systematic Review and Meta-Analysis. 
In the systematic review and meta-analysis conducted 
by Li et al (13), early norepinephrine use was compared 
with late initiation of norepinephrine in patients with 
septic shock. A random-effects model was used to pool 
studies with significant heterogeneity. Five studies with 
a combined sample size of 929 adult patients were in-
cluded (29–32). The five studies were analyzed for the 
primary endpoint of short-term mortality. Short-term 
mortality was defined as hospital, 28-day, and 30-day 
mortality. Three (60%) of the included studies were ana-
lyzed for these secondary outcomes: ICU length of stay, 
time to achieve target mean arterial pressure (MAP), 
and volume of IV fluids (IVFs) within 6 hours (29–32).
While there was no significant heterogeneity found 
among the studies for short-term mortality (I2 = 0%), 
ICU length of stay (I2 = 0%), and time to target MAP 
(I2 = 0%), there was substantial heterogeneity present for 
volume of IVF within 6 hours (I2 = 94%). Short-term 
mortality was lower in the early norepinephrine group 
compared with the late norepinephrine group (OR, 0.45; 
95% CI, 0.34–0.61). There was no significant difference 
in ICU length of stay (mean difference = –0.11 d; 95% 
CI, –1.27 to 1.05). However, the early norepinephrine 
group had shorter time to target MAP (mean differ-
ence = –1.39 hr; 95% CI, –1.81 to –0.96 hr) and used 
less IVF within 6 hours (mean difference = –0.50 L; 95% 
CI, –0.68 to –0.32 L).
Norepinephrine remains the first-line vasopressor 
for septic shock (33). Although the surviving sepsis 
guidelines recommend use of vasopressors early in the 
course of septic shock, the impact on clinical outcomes 
remains unclear (34). The 2018 update to the Surviving 
Sepsis Guidelines recommends rapid administration 
of crystalloid within the first hour of septic shock 
and early application of vasopressors in patients who 
remain hypotensive despite fluid resuscitation (34). 
Consistent with the guidelines, the findings of this 
meta-analysis support the use of norepinephrine early 
in the course of septic shock. Early administration of 
norepinephrine shortens the duration of hypotension 
and provides adequate perfusion to prevent organ 
damage (34). Additionally, the use of vasopressors 
early may minimize the use of unnecessary fluids be-
yond the initial resuscitation period.
Although the aforementioned guideline recommen-
dations for early vasopressor initiation are part of the 
1-hour sepsis bundle, the most optimal timing is still 
unclear. The studies included in this meta-analysis had 
variable definitions of early versus late vasopressor ad-
ministration. The definitions of early norepinephrine 
ranged from prior to fluid resuscitation to less than 
6 hours from onset of septic shock. As fluid overload 
is associated with increased mortality, future studies 
should better delineate a more explicit definition of 
early norepinephrine initiation. Future studies should 
also investigate the impact of early norepinephrine 
use on long-term mortality, including the upcoming 
Crystalloid Liberal or Vasopressors Early Resuscitation 
in Sepsis trial (35).
Sedation and Analgesia
Nonsedation or Light Sedation in Critically Ill, 
Mechanically Ventilated Patients. The Nonsedation or 
Light Sedation in Critically Ill, Mechanically Ventilated 
Patients (NONSEDA) trial was a multicenter, ran-
domized, nonblinded study evaluating light sedation 
versus nonsedation in mechanically ventilated patients 
(9). Patients were randomized to receive either non-
sedation or light sedation, defined as a Richmond 
Agitation-Sedation Scale (RASS) –2 to –3. Patients in 
Bissell et al
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the light sedation group received propofol for the first 
48 hours of mechanical ventilation then transitioned to 
a continuous midazolam infusion per study protocol.
There was no difference in all-cause 90-day mor-
tality between the nonsedation and light seda-
tion groups (42.4% vs 37.0%; 95% CI, –2.2 to 12.2; 
p = 0.65). Secondary outcomes included delirium-free 
days, days without mechanical ventilation, and occur-
rence of thromboembolic events, of which no signifi-
cant differences were found. Within the nonsedation 
group, 27.0% required sedation on day 1 and 38.4% 
received sedation at some time during their ICU stay, 
with delirium being cited as the most frequent reason. 
The safety outcome of self-extubation requiring rein-
tubation within 24 hours was more common in the 
nonsedation group versus light sedation group (8.9% 
vs 4.0%, p = 0.01).
Sedation in ventilated patients has been an impor-
tant topic, yet ideal standard definitions for light seda-
tion and established protocols are not commonplace. A 
meta-analysis of 8,001 mechanically ventilated patients 
found a significantly higher mortality risk with those 
receiving deeper levels of sedation (p = 0.003). Those 
with lighter sedation were at risk of agitation-related 
adverse events such as unintentional extubation 
(p = 0.002); however, no difference in delirium was 
identified (36). The Pain, Agitation/Sedation, Delirium, 
Immobility, and Sleep (PADIS) guidelines favors non-
benzodiazepines for sedation owing to shorter time to 
extubation (37). Light sedation is recommended over 
deep sedation; however, the PADIS guidelines do not 
specifically address nonsedation strategies in mechan-
ically ventilated patients.
Prior to the NONSEDA trial, Strøm et al (38) evalu-
ated a nonsedation strategy in a single-site medical/
surgical ICU. The investigators randomized 140 me-
chanically ventilated patients to receive either nonseda-
tion or sedation protocols. Converse to the NONSEDA 
trial, Strøm et al (38) found a significant improvement 
in length of ventilation, ICU length of stay and hospital 
length of stay when the nonsedation strategy was used. 
Possible reasons the NONSEDA trial did not replicate 
these results include the similar RASS scores between 
groups and the high prevalence of sedation utilization 
in the nonsedation group. The results of the NONSEDA 
trial suggest that a nonsedation strategy is noninferior 
to light sedation and that light sedation may be a safer 
strategy to prevent harmful adverse effects such as 
self-extubation. Nonsedation may be appropriate for a 
select population but further trials are needed.
Dexmedetomidine for Reduction of Atrial 
Fibrillation and Delirium After Cardiac Surgery: 
A Randomized Placebo-Controlled Trial. 
Dexmedetomidine possesses sedative and sympatholytic 
properties with minimal respiratory depression (10). 
Previous data regarding use of dexmedetomidine 
in cardiac surgery to reduce atrial fibrillation (AF) 
have been inconclusive (39, 40). Dexmedetomidine 
has been shown to reduce delirium postcardiac sur-
gery; however, guidelines do not mention the use of 
dexmedetomidine in this patient population (41, 42). 
Guideline recommendations support the use of pro-
pofol over benzodiazepines for intubated patients 
and dexmedetomidine use in mechanically ventilated 
patients when agitation is inhibiting weaning of seda-
tion and extubation; however, recommend against use 
of dexmedetomidine to prevent delirium (37).
Turan et al (10) conducted a multicenter, random-
ized, placebo-controlled trial to evaluate dexme-
detomidine’s effect on a coprimary outcome of atrial 
arrhythmia and delirium in adult patients undergo-
ing cardiac surgery with cardiopulmonary bypass and 
heart rate greater than 50 beats/min. Secondary out-
comes included kidney function, incisional pain, brad-
ycardia and hypotension requiring treatment, stroke, 
myocardial infarction, venous thromboembolism, sur-
gical site infection, and mortality. Dexmedetomidine 
was started preincision at 0.1 µg/kg/hr and escalated 
to 0.2 µg/kg/hr at bypass termination. Postsurgery, the 
infusion was increased to 0.4 µg/kg/hr and continued 
for 24 hours. Managing providers reduced the dose 
if hemodynamics necessitated, and additional seda-
tives, such as propofol and benzodiazepines, were used 
based on discretion.
A total of 400 and 398 patients were randomized 
in the dexmedetomidine and placebo groups, respec-
tively, when the trial was terminated early. No differ-
ence in postoperative AF was observed in patients 
receiving dexmedetomidine compared with placebo 
(30% vs 34%; RR, 0.91; p = 0.34) and there was a 
nonsignificant increase in delirium incidence among 
patients in the dexmedetomidine group (17% vs 12%; 
RR, 1.48; p = 0.026). More clinically significant hypo-
tension was observed in the dexmedetomidine group 
(57% vs 36%) and in a post hoc analysis, delirium 
was more likely in patients with clinically significant 
Systematic Review
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hypotension (p = 0.009). These findings were consistent 
across sites; patient demographics and measures were 
relatively homogenous. Amiodarone prophylaxis was 
prohibited and beta-blocker doses were not reported. 
Additionally, benzodiazepine use was not described.
Turan et al (10) demonstrated dexmedetomi-
dine failed to reduce incidence of AF and observed 
increased hypotension and delirium, even at relatively 
low doses. Based on lack of evidence to support dex-
medetomidine to reduce AF and finding increased 
delirium postcardiac surgery in this appropriately 
powered trial, its use should be reserved for patients 
requiring light sedation.
Stroke
Endovascular Thrombectomy With or Without 
IV Alteplase in Acute Stroke (DIRECT-MT). 
DIRECT-MT was a prospective, randomized, open-
label trial of 656 patients with acute ischemic stroke (12). 
Adult patients with a large vessel occlusion and neu-
rologic deficit, indicated with National Institute of 
Health Stroke Scale (NIHSS) of at least two, who 
could also be treated with alteplase within 4.5 hours 
of symptom onset were included in the trial. Patients 
with baseline disability, defined as score greater than 2 
on modified Rankin Scale (mRS) or contraindication 
to alteplase were excluded. Patients were randomized 
to either thrombectomy alone (n = 327) or combina-
tion thrombectomy plus alteplase, dosed at 0.9 mg/kg 
to a maximum of 90 mg (n = 329).
Patient characteristics at baseline were similar in 
both groups with a median NIHSS score of 17. In an 
intent-to-treat analysis, the adjusted common OR for 
mRS score at 90 days was 1.07 (95% CI, 0.81–1.40; 
p = 0.04) concluding thrombectomy alone was non-
inferior to combination thrombectomy. Mortality, se-
rious adverse events, and procedural complications 
were similar between groups.
Retrospective studies and meta-analyses have pro-
duced conflicting results on benefits of IV thrombolyt-
ics prior to thrombectomy; thus, this is the first RCT to 
show noninferiority of thrombectomy alone over com-
bination therapy (43–46). Despite achieving success-
ful reperfusion in most patients, only ~36% of patients 
had mRS of 0–2 at 90 days displaying the impact of 
multiple factors on outcomes.
Limitations of this study are primarily related to 
practice patterns in China differing to those in the 
United States. Time from triage to randomization 
was longer due to workflow (e.g., fewer prehospital 
stroke activations and lengthy discussions with mul-
tiple family members regarding informed consent of 
receiving alteplase). Thus, median time from symptom 
onset to randomization was almost 170 minutes, sig-
nificantly higher than a prior thrombectomy trial (47). 
Additionally, the causes of stroke differ in Asian versus 
non-Asian populations, making these results less 
generalizable.
Alternative thrombolytics, such as tenecteplase, have 
shown potentially improved outcomes. Encouraging 
early reperfusion data was observed with tenecteplase 
in a separate RCT that compared alteplase to 
tenecteplase prior to thrombectomy (47). Thus, similar 
trial design with tenecteplase may produce more com-
pelling data for the combination therapy given the ease 
of administration and promising reperfusion data (47). 
Given the adverse events, cost, and strict exclusion cri-
teria surrounding IV alteplase, it may be reasonable to 
consider thrombectomy alone for patients in whom 
risks of thrombolytic therapy outweigh the benefits.
CONCLUSIONS
This clinical review provides perspectives on influ-
ential critical care pharmacotherapy publications in 
2020 along with insight on clinical practice impact. 
Limitations of the article include the possibility of 
missing relevant literature among unreviewed journals 
as well as future considerations for ongoing publica-
tions surrounding sepsis, sedation, COVID-19, and 
stroke. Further trials are needed to answer numerous 
clinical questions surrounding these highly prevalent 
disease states.
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